| Detected | Trial | Change |
|---|---|---|
| 2026-06-10 | NCT07303283 Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma |
Primary endpoint(s) modified |
| 2026-06-10 | NCT07303283 Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma |
Enrollment reduced: 218 -> 140 participants |
| 2026-06-10 | NCT07303283 Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma |
date change Primary completion pushed: 2030-04-15 -> 2030-08-31 |
| 2026-06-10 | NCT07303283 Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma |
date change Completion pushed: 2033-04-15 -> 2033-08-31 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-04 | NCT07627321 Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for… | Phase 2 | Not Yet Recruiting |
| 2026-05-20 | NCT07598318 Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With… | Phase 2/3 | Not Yet Recruiting |
| 2026-05-15 | NCT07589049 Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable… | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07459296 | Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC | Nasopharyngeal Carcinoma (NPC) | Recruiting |
| NCT07481799 | Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive… | Oligo-metastatic Cancer | Recruiting |
| NCT07524413 | Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk… | Nasopharyngeal Cancinoma (NPC) | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT07598318 | Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With… | Cholangiocarcinoma | Not Yet Recruiting |
| Phase 2 | |||
| NCT06959108 | Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination… | Locally Advanced Head and Neck Squamous Cell Carcinoma | Recruiting |
| NCT07496190 | Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy… | Nasopharyngeal Cancinoma (NPC) | Recruiting |
| NCT07536789 | Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma | Hepato Cellular Carcinoma (HCC) | Recruiting |
| NCT07522879 | A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for… | Adenoid Cystic Carcinoma | Recruiting |
| NCT07331428 | MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC | Nasopharyngeal Carcinoma | Not Yet Recruiting |
| NCT07381075 | A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or… | Head and Neck Squamous Cell Carcinoma | Not Yet Recruiting |
| NCT05126719 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent… | Recurrent or Metastatic Nasopharyngeal Carcinoma | Active, Not Recruiting |
| NCT07394244 | Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma (CSCC) | Not Yet Recruiting |
| NCT07490119 | Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS… | RAS Wild Type mCRC | Not Yet Recruiting |
| NCT07518979 | EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant… | Penile Cancer | Not Yet Recruiting |
| NCT07531979 | Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and… | ESCC | Not Yet Recruiting |
| NCT07555860 | Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally… | Nasopharyngeal Carcinoma | Not Yet Recruiting |
| NCT07579598 | ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma | Adenoid Cystic Carcinoma of the Head and Neck | Not Yet Recruiting |
| NCT07589049 | Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable… | Head and Neck Squamous Cell Carcinoma | Not Yet Recruiting |
| NCT07627321 | Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for… | NSCLC (Advanced Non-small Cell Lung Cancer) | Not Yet Recruiting |
| NCT07303283 | Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma (NPC) | Not Yet Recruiting |
| Phase 1 | |||
| NCT07054307 | MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or… | Penile Cancer | Recruiting |
| NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric… | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | Recruiting |